Briacell Therapeutics Corp
BCTX0.741USD
-0.003-0.40%
Market hours （ET）Quotes delayed by 15 min
4.86MMarket Cap
LossP/E TTM
More Details of Briacell Therapeutics Corp Company
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Company Info
Ticker SymbolBCTX
Company nameBriacell Therapeutics Corp
IPO dateOct 12, 2006
CEODr. William V. Williams, M.D.
Number of employees17
Security typeOrdinary Share
Fiscal year-endOct 12
AddressSuite 300 - Bellevue Centre, 235 -15th Street
CityWEST VANCOUVER
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeV7T 2X1
Phone16049211810
Websitehttps://briacell.com/
Ticker SymbolBCTX
IPO dateOct 12, 2006
CEODr. William V. Williams, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. William V. Williams, M.D.
Dr. William V. Williams, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
10.81K
+2.10%
Mr. Jamieson Bondarenko
Mr. Jamieson Bondarenko
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
10.77K
+34.77%
Mr. Vaughn C. Embro-pantalony, CPA
Mr. Vaughn C. Embro-pantalony, CPA
Independent Director
Independent Director
1.19K
+22.93%
Mr. Gadi Levin
Mr. Gadi Levin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
187.00
--
Mr. Martin E. Schmieg, CPA
Mr. Martin E. Schmieg, CPA
Independent Director
Independent Director
--
--
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Independent Director
Independent Director
--
-100.00%
Dr. Giuseppe Del Priore, M.D.
Dr. Giuseppe Del Priore, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Miguel A. Lopez-Lago
Dr. Miguel A. Lopez-Lago
Chief Scientific Officer
Chief Scientific Officer
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Dr. William V. Williams, M.D.
Dr. William V. Williams, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
10.81K
+2.10%
Mr. Jamieson Bondarenko
Mr. Jamieson Bondarenko
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
10.77K
+34.77%
Mr. Vaughn C. Embro-pantalony, CPA
Mr. Vaughn C. Embro-pantalony, CPA
Independent Director
Independent Director
1.19K
+22.93%
Mr. Gadi Levin
Mr. Gadi Levin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
187.00
--
Mr. Martin E. Schmieg, CPA
Mr. Martin E. Schmieg, CPA
Independent Director
Independent Director
--
--
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Independent Director
Independent Director
--
-100.00%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Heights Capital Management, Inc.
5.70%
Iroquois Capital Management, LLC
3.19%
L5 Capital Inc.
0.99%
Lynwood Capital Management Inc.
0.61%
3I Management LLC
0.52%
Other
88.99%
Shareholders
Shareholders
Proportion
Heights Capital Management, Inc.
5.70%
Iroquois Capital Management, LLC
3.19%
L5 Capital Inc.
0.99%
Lynwood Capital Management Inc.
0.61%
3I Management LLC
0.52%
Other
88.99%
Shareholder Types
Shareholders
Proportion
Investment Advisor
5.81%
Hedge Fund
3.19%
Corporation
1.30%
Investment Advisor/Hedge Fund
1.13%
Individual Investor
0.13%
Research Firm
0.03%
Other
88.41%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
65
831.24K
8.14%
-645.33K
2025Q1
68
476.26K
7.27%
-513.92K
2024Q4
65
403.53K
10.88%
-198.25K
2024Q3
64
441.30K
30.40%
+131.88K
2024Q2
63
437.48K
31.09%
+121.43K
2024Q1
62
332.09K
21.52%
-17.16K
2023Q4
67
402.86K
34.69%
+35.57K
2023Q3
74
369.20K
35.11%
-158.11K
2023Q2
84
434.95K
41.59%
-338.84K
2023Q1
83
423.04K
40.96%
-355.97K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Heights Capital Management, Inc.
489.20K
7.46%
+489.20K
--
Apr 24, 2025
L5 Capital Inc.
174.03K
2.65%
+4.50K
+2.65%
Dec 10, 2024
Lynwood Capital Management Inc.
106.52K
1.62%
+1.14K
+1.08%
Mar 31, 2024
3I Management LLC
91.69K
1.4%
-277.31K
-75.15%
Mar 31, 2025
Copia Fund (Cayman) LP
54.56K
0.83%
+54.56K
--
Dec 29, 2023
UBS Financial Services, Inc.
19.07K
0.29%
+16.43K
+622.20%
Mar 31, 2025
Williams (William V)
10.81K
0.16%
+222.00
+2.10%
Dec 09, 2024
Bondarenko (Jamieson)
10.77K
0.16%
+2.78K
+34.77%
Dec 09, 2024
Group One Trading, L.P.
2.92K
0.04%
-1.60K
-35.37%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 03, 2025
Merger
15<1
Jan 03, 2025
Merger
15<1
Jan 03, 2025
Merger
15<1
Jan 03, 2025
Merger
15<1
Date
Type
Ratio
Jan 03, 2025
Merger
15<1
Jan 03, 2025
Merger
15<1
Jan 03, 2025
Merger
15<1
Jan 03, 2025
Merger
15<1
